| DEVELOPMENT | "G" will employ GPC's proprietary Reverse Genomics technology to perform compound mode-of-action studies on up to 50 of "B" antibacterial development candidates. "B" will use the results to prioritize candidates for its drug development |
| AGREEMENT | This data is not available for free |
| UPDATE | 08.00 |
| LITERATURE REF. | This data is not available for free |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |